Wall Street analysts predict that Juno Therapeutics, Inc. (NASDAQ:JUNO) will report sales of $19.16 million for the current quarter, according to Zacks. Five analysts have made estimates for Juno Therapeutics’ earnings. The lowest sales estimate is $17.00 million and the highest is $21.30 million. Juno Therapeutics reported sales of $20.83 million during the same quarter last year, which indicates a negative year-over-year growth rate of 8%. The firm is expected to report its next quarterly earnings results on Wednesday, November 8th.

According to Zacks, analysts expect that Juno Therapeutics will report full-year sales of $19.16 million for the current fiscal year, with estimates ranging from $66.00 million to $83.10 million. For the next year, analysts forecast that the firm will post sales of $69.99 million per share, with estimates ranging from $50.00 million to $83.10 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of research firms that follow Juno Therapeutics.

Juno Therapeutics (NASDAQ:JUNO) last posted its earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($0.96) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.72) by ($0.24). The firm had revenue of $21.30 million for the quarter, compared to analyst estimates of $15.59 million. Juno Therapeutics had a negative net margin of 354.36% and a negative return on equity of 27.10%. The company’s revenue for the quarter was down 22.8% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.64) earnings per share.

A number of brokerages have recently issued reports on JUNO. Zacks Investment Research cut shares of Juno Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, August 3rd. Morgan Stanley increased their price objective on shares of Juno Therapeutics from $26.00 to $27.00 and gave the company an “equal weight” rating in a research note on Monday, August 7th. FBR & Co restated a “hold” rating on shares of Juno Therapeutics in a research note on Thursday, May 18th. Vetr cut shares of Juno Therapeutics from a “buy” rating to a “hold” rating and set a $28.85 price objective for the company. in a research note on Monday, June 26th. Finally, BidaskClub upgraded shares of Juno Therapeutics from a “hold” rating to a “buy” rating in a research note on Tuesday, June 20th. Three investment analysts have rated the stock with a sell rating, six have issued a hold rating and nine have given a buy rating to the company’s stock. The company presently has an average rating of “Hold” and an average target price of $34.88.

Juno Therapeutics (NASDAQ JUNO) opened at 45.32 on Thursday. Juno Therapeutics has a 1-year low of $17.52 and a 1-year high of $45.75. The firm’s market capitalization is $4.75 billion. The firm’s 50-day moving average is $32.75 and its 200-day moving average is $26.72.

In other Juno Therapeutics news, CFO Steve Harr sold 8,750 shares of the stock in a transaction dated Tuesday, June 27th. The shares were sold at an average price of $30.00, for a total transaction of $262,500.00. Following the sale, the chief financial officer now owns 736,189 shares of the company’s stock, valued at approximately $22,085,670. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Richard Klausner sold 12,000 shares of the stock in a transaction dated Thursday, September 7th. The stock was sold at an average price of $42.66, for a total transaction of $511,920.00. Following the sale, the director now directly owns 783,536 shares in the company, valued at approximately $33,425,645.76. The disclosure for this sale can be found here. In the last three months, insiders have sold 8,078,369 shares of company stock worth $218,620,477. Insiders own 15.26% of the company’s stock.

Large investors have recently modified their holdings of the business. The Manufacturers Life Insurance Company grew its holdings in Juno Therapeutics by 7.2% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 3,405 shares of the biopharmaceutical company’s stock worth $102,000 after acquiring an additional 228 shares during the last quarter. Pacad Investment Ltd. bought a new stake in Juno Therapeutics during the 2nd quarter worth about $105,000. QS Investors LLC bought a new stake in Juno Therapeutics during the 2nd quarter worth about $135,000. Great West Life Assurance Co. Can grew its holdings in Juno Therapeutics by 80.5% during the 1st quarter. Great West Life Assurance Co. Can now owns 8,518 shares of the biopharmaceutical company’s stock worth $189,000 after acquiring an additional 3,800 shares during the last quarter. Finally, Nisa Investment Advisors LLC bought a new stake in Juno Therapeutics during the 1st quarter worth about $200,000. 70.76% of the stock is currently owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY WARNING: “$19.16 Million in Sales Expected for Juno Therapeutics, Inc. (JUNO) This Quarter” was published by American Banking News and is the property of of American Banking News. If you are reading this news story on another publication, it was illegally copied and republished in violation of United States & international copyright law. The legal version of this news story can be viewed at https://www.americanbankingnews.com/2017/09/14/19-16-million-in-sales-expected-for-juno-therapeutics-inc-juno-this-quarter.html.

About Juno Therapeutics

Juno Therapeutics, Inc (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells.

Get a free copy of the Zacks research report on Juno Therapeutics (JUNO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Juno Therapeutics (NASDAQ:JUNO)

Receive News & Ratings for Juno Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juno Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.